Continuous Renal Replacement Therapy Market Segments and Growth by 2030

[Research Report] The continuous renal replacement therapy market size is projected to grow from US$ 1.42 billion in 2022 to US$ 2.75 billion by 2030. The market is estimated to register a CAGR of 8.7% from 2022 to 2030.

Market Insights and Analyst View:

This report includes growth prospects owing to the current continuous renal replacement therapy market trends and their foreseeable impact during the forecast period.

Continuous renal replacement therapy (CRRT) is a life-saving intervention for patients suffering severe acute kidney injury (AKI), fluid overload, and uremia with potentially fatal metabolic abnormalities. Factors such as the increased demand for pediatric CRRT devices and the high prevalence of chronic diseases leading to kidney diseases propel the continuous renal replacement therapy market growth. However, a significant chance of a major adverse kidney event (MAKE) limits the market growth.

Market Drivers:

High Incidence of Chronic Diseases Leading to Kidney Diseases

1 in 10 people globally is affected by chronic kidney disease (CKD), which is a common and life-threatening condition. From 2015 to 2019, diabetes and high blood pressure were the two major causes of kidney failure in 75% of the total failure cases. According to estimates released by the National Kidney Foundation in 2020, in the US ~30% of the diabetic population above 20 years of age is at risk of developing CKD in their lifetime. Moreover, this disease caused more deaths than prostate cancer or breast cancer in 2020, and it is an under-recognized emergency health disorder. 1 in 3 American adults (i.e., ~80 million people) is at risk of CKD, which is now identified as a clear risk factor for AKI. Decreased glomerular filtration rate (GFR) and increased proteinuria are strongly associated with an AKI.

According to the National Institute of Health, the occurrence of AKI is rising in developed countries. Its prevalence in hospital inpatients is predicted to reach 15%, and it is higher in critically ill patients i.e., 60%. An AKI incidence in inpatients across the world ranges from 0.7% to 31%; patients in intensive care units (ICUs) experience an incidence of more than 50%. A range from 3% to 13% of patients having AKI need RRT and 40% of these patients are estimated to need CRRT for more than 90 days. Thus, the high prevalence of chronic diseases leading to kidney diseases boosts the continuous renal replacement therapy market growth.

Major ill effects associated with CRRT include hypotension, tachycardia, and other arrhythmias, which may adversely affect the patient's condition or impede their recovery. Furthermore, the CRRT circuit might facilitate the faster clearance of micronutrients, trace elements, and/or therapeutic medicines, which can lead to low or irregular concentrations in blood and tissues, thereby causing adverse effects and/or loss of therapeutic effect. Thus, the adverse effects restrict the continuous renal replacement therapy market.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Continuous Renal Replacement Therapy Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Report Segmentation and Scope:

The continuous renal replacement therapy market analysis has been carried out by considering the following segments: product, modality, and end user.

Segmental Analysis:

The continuous renal replacement therapy market, by product, is segmented into dialysates and replacement fluids, disposables, bloodline sets and tubes, CRRT systems, and hemofilters. The CRRT systems segment accounted for the largest share of the market in 2022. The hemofilters segment is anticipated to register the highest CAGR in the market during 2022–2030.

By modality, the continuous renal replacement therapy market is segmented into continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF), continuous venovenous hemodialysis (CVVHD), and slow continuous ultrafiltration (SCUF). The continuous venovenous hemofiltration (CVVH) segment held the largest share of the market in 2022. The market for the continuous venovenous hemodiafiltration (CVVHDF) segment is expected to register the highest CAGR during 2022–2030.

By end user, the continuous renal replacement therapy market is segmented into hospitals, ambulatory care centers, home care, and others. In 2022, the hospitals segment dominated the continuous renal replacement therapy market share. However, the home monitoring segment is expected to register the highest CAGR during 2022–2030.

Regional Analysis:

The scope of the continuous renal replacement therapy market report encompasses North America (US, Canada, and Mexico), Europe (Spain, UK, Germany, France, Italy, and Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

In terms of revenue, in 2022, North America dominated the continuous renal replacement therapy market share. The market in Asia Pacific is anticipated to register the highest CAGR during 2022–2030. The continuous renal replacement therapy market in Asia Pacific is growing with the improving healthcare infrastructure and the adoption of innovative CRRT technologies, both of which can be associated with rising healthcare expenditure. Additionally, strategic initiatives by the market players to expand their presence in Asia Pacific, such as collaborations with local healthcare providers, favor the market growth in the region.

Continuous Renal Replacement Therapy Market Regional Insights

The regional trends and factors influencing the Continuous Renal Replacement Therapy Market throughout the forecast period have been thoroughly explained by the analysts at The Insight Partners. This section also discusses Continuous Renal Replacement Therapy Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Continuous Renal Replacement Therapy Market Report Scope

Continuous Renal Replacement Therapy Market Players Density: Understanding Its Impact on Business Dynamics

The Continuous Renal Replacement Therapy Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Continuous Renal Replacement Therapy Market are:

1. Baxter International Inc
2. Asahi Kasei
3. Fresenius Medical Care
4. Medica S.p.A.
5. Medtronic Plc

Disclaimer: The companies listed above are not ranked in any particular order.

Competitive Landscape and Key Companies:

The continuous renal replacement therapy market report is focused on prominent players in the market such as Baxter International Inc, Asahi Kasei, Fresenius Medical Care, Medica S.p.A., Medtronic Plc, B. Braun, Nikkiso Co Ltd, Toray Medical Co Ltd, Infomed SA, and Quanta Dialysis Technologies Inc. The continuous renal replacement therapy market forecast can help stakeholders plan their growth strategies. These companies focus on launching new technologies, upgrading existing products, and expanding their businesses to meet the growing consumer demand worldwide.

• In April 2022, the US Food and Drug Administration (FDA) provided 510(k) clearance for the ST Set by Baxter International Inc. for its use in continuous renal replacement therapy (CRRT). The ST Set is a pre-connected, disposable, extracorporeal (outside the body) circuit that provides blood purification through a semipermeable membrane to be used with the PrisMax or Prismaflex control units (monitors).
• In March 2022, Nipro Medical Corporation (Nipro), a leading manufacturer and supplier of renal, vascular, and medical-surgical products, announced the commercial launch of the SURDIAL DX Hemodialysis System in the US. SURDIAL DX is a state-of-the-art hemodialysis system designed to create an optimal dialysis treatment experience for patients and clinicians. Manufactured in Japan, the product is based is based on over 35 years of expertise in renal device innovation at Nipro’s parent company, Nipro Corporation.